AzTrials
AzTrials

Skin Aging on FaceNR-RADIANCENCT07774000

Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging

A study testing Topical niacinamide riboside in people with Skin Aging on Face and Skin Care Dermocosmetics, run by ChromaDex, Inc. at 1 site in South Africa.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Niacinamide riboside (topical NR, also known as nicotinamide riboside) is an endogenous compound and a precursor (building block) to the essential cellular co-enzyme, nicotinamide adenine dinucleotide (NAD+). Research published by Maussudi et al. Read more about this study

Who is it for?
Ages 30 to 60 years, women onlyHealthy volunteers can take part
What is being tested?
Topical niacinamide riboside
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
140 participants
Where
1 siteSouth Africa
Study dates
17 Aug 2026to 31 Mar 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 60 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Open to all races provided they meet the inclusion and exclusion criteria below:
  • Gender: Female
  • Age: 30 to 60 years old
  • Phototype: I to VI
  • Subject presenting with fines lines/ wrinkles as Crow's feet, inclusion grade ≥ 3 and ≤ 6 on a 10-points scale.
  • Subject presenting with one or more visible signs of skin aging on face (example of signs of skin aging: wrinkles and fine lines, lack of firmness, lack of radiance, pigmented spots, dry and rough skin, visible pores, skin sagging).
  • Subject is not currently using NAD+ or another product containing Vitamin B3 (niacin, niacinamide, nicotinamide, nicotinamide riboside, nicotinamide mononucleotide, myristyl nicotinate, etc.) administered topically, orally intravenously, or through any form of injection, as a part of their current routine or 4 weeks before starting study. The only permitted exception is the use of a multivitamin that contains niacin or nicotinamide. If this is the case, the product and dose of niacin or nicotinamide should be documented at screening and continuation of use of the product should be documented at each site visit.
  • Willingness to maintain current lifestyle, wellness and skin care routines (with the exception of the inclusion of the product requirements incorporated into the study protocol).

Who cannot join

  • Subject not providing consent;
  • Subject not complying with protocol requirements;
  • Subject of whom a health condition has changed since the inclusion visit in the I.E.C database, making the subject ineligible or places her at undue risk;
  • Active cancer diagnosis or diagnosis of cancer of any kind less than three years since remission, liver disease, kidney disease, or uncontrolled diabetes;
  • Pregnancy, actively breastfeeding, or not willing to take necessary precautions to avoid a pregnancy during the study;
  • Subject having a medical treatment, recent vaccination or expecting to be vaccinated during the study, that makes the subject ineligible or places her at undue risk, in particular, medical treatment (either oral or topical) containing tretinoin or isotretinoin during the 3 months before the starting day of the study;
Show all 16Show fewer
  • Subject having a background of intolerance or allergy to cosmetics, NAD+ or any vitamin B3 derivative, ingredients in the auxiliary products or to other substances that makes the subject ineligible or places her at undue risk;
  • Subject having visible traces of irritation or any other abnormality on the concerned area;
  • Subject having skin recently exposed to excessive sunlight (natural or artificial) within 4 weeks preceding the inclusion;
  • Subject having undergone surgery, chemical or physical treatment to the concerned area in the last 12 months (no injection during the last 6 months);
  • Subject having applied anti-wrinkle/anti-aging/firming products on concerned area during the 4 weeks before the starting day of the study;
  • Subject having had any cosmetic procedures performed in the last six months (including Botox, peels, laser, etc.);
  • Subject having applied NAD+/B-vitamin products on the concerned area during the 4 weeks before the starting day of the study;
  • Subject having modified his/her cosmetic habits (on the concerned area by the study) during the last 2 weeks, making her ineligible;
  • Subject having applied cosmetic or pharmaceutical products (other than their usual cleanser) to the areas of concern during the 96 hours before the starting day of the study and on the day of inclusion;
  • Subject having applied any cosmetic or pharmaceutical products (only water allowed) to the areas of concern the day of inclusion.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Manoj Choudhry contact

+27 21 204 4886

manoj.choudhry@iecas.co.za

South Africa1 site, 1 recruiting

  • I.E.C. Afrique du Sud

    Cape Town, Western Cape, 7925

    Manoj Choudhry, +021 447 4366, studies@iecas.co.za

    Manoj Choudhry

    Recruiting

Other trials in South Africa

About this study

Official title: Randomized, Placebo-controlled Clinical Study for the Evaluation and the Comparison of the Dose-response Efficacy of 4 Cosmetic Investigational Products (3 Active, 1 Placebo; 1 Tested Investigational Product Per Subject), After Repeated Applications for 12 Weeks, Under Normal Conditions of Use, in Female Adult Subjects

Niacinamide riboside (topical NR, also known as nicotinamide riboside) is an endogenous compound and a precursor (building block) to the essential cellular co-enzyme, nicotinamide adenine dinucleotide (NAD+). Research published by Maussudi et al. 2012 demonstrated that skin NAD+ levels were negatively correlated with age in both males and females, and aged skin was also correlated to an increase in DNA damage. Therefore, it is proposed that supporting skin NAD+ with precursors such as NR may be a strategy to combat DNA damage that leads to undesirable signs of skin aging, thus supporting skin cell resilience. The use of NR as a dietary supplement has produced effective, efficient, and reproducible increases in NAD+ in humans. However, the role of topically applied NR for skin aging requires further investigation.

Though not measuring NAD+ directly, this study will explore if topically applied NR reduces the signs of skin aging that may result from cellular NAD+ deficiency. It is hypothesized that the addition of NR to a general skin care regimen will result in healthier, more youthful appearing skin over 12 weeks.

Read more

The goal of this interventional clinical trial is to identify the most effective, tolerable, and efficient dose of NR for attenuating quantitative and qualitative indicators of facial skin aging in women ages 30-60. The three primary outcome measures are

  • Changes in skin biological age,
  • Quantitative reduction in fine lines and wrinkles near the eye, and
  • Changes in skin firmness and tightening.

Secondary quantitative and qualitative outcomes include

  • Changes to pores, texture, redness, skin tone evenness, radiance, plumpness, and firmness on the global face.
  • Changes in skin moisture and skin barrier integrity, and
  • Participant perception of perceived efficacy, acceptability, and irritation.

Skin imaging will also be employed in the study.

Participants will be randomized into one of four test product groups:

  • Placebo
  • 2.5% NR,
  • 5% NR, or
  • 10% NR.

The test product will be provided in a dry nanofiber sachet, and the percentage of NR is an estimate based on the final concentration of the applied material when mixed in serum.

Following facial cleansing with the provided cleanser, study participants will prepare the test product (immediately before application) by dissolving a single sachet in the provided standardized gel serum. Following application, participants will apply the provided moisturizer and UV serum. Product application will occur twice daily for 84 days (12 weeks). In-clinic assessments will be performed at baseline and days 28, 56, and 84. Participants will also complete at home questionnaires on days 14 and 42. Adverse events and responses will be documented in participant diaries and immediately reported to the clinical research team.

Being tested
Topical niacinamide riboside, Placebo
Keywords
nicotinamide riboside, niacinamide riboside, nicotinamide adenine dinucleotide, skin aging, skin aging clock, topical, skin care

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Topical niacinamide ribosideOther

    Also called Niagen NanoCloud, Nicotinamide riboside

    Niacinamide chloride (NR) prepared in a dry nanofiber pillow will be applied to the skin using a standardized gel serum twice daily, for 12 weeks. NR is a precursor to the essential cellular co-enzyme, NAD+, which has been directly associated with the molecular hallmarks of aging.

  • PlaceboOther

    Topical Skin Care Product: Placebo prepared in a a dry nanofiber pillow, applied topically to the face, twice daily for 12 weeks.

Study groups in NCT07774000
Study groupRoleWhat they receive
PlaceboPlacebo comparatorThe participants randomized to this group will receive a product that results in 0% of NR per application.
Receives: Other: Placebo
2.5% NRExperimentalThe participants randomized to this group will receive a product that results in approximately 2.5% of NR per application.
Receives: Other: Topical niacinamide riboside
5% NRExperimentalThe participants randomized to this group will receive a product that results in approximately 5% of NR per application.
Receives: Other: Topical niacinamide riboside
10% NRExperimentalThe participants randomized to this group will receive a product that results in approximately 10% of NR per application.
Receives: Other: Topical niacinamide riboside

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in skin's biological age

    Dermal curette sampling of the skin at baseline and day 84 to evaluate changes in epigenetic markers of skin aging.

    Measured: baseline and day 84

  2. Quantitative change in fine lines and wrinkles

    The severity of fine lines and wrinkles will be clinically scored by a trained assessor evaluating 1) the Crow's feet area near the eye, and 2) the area underneath the eye, separately. Scoring for each area will range from 0 to 9, and intermediate scores (including fractions and decimals) will not be allowed. A score of 0 will indicate "no wrinkles," whereas a score of 9 will indicate "very marked wrinkles, accounting for number, surface and depth."

    Measured: baseline and days 28, 56, and 84

  3. Quantitative changes in skin firmness and tightness

    Changes in skin firmness and tightness will be measured by a Cutometer™ to objectively assess and compare the effect of the product on the skin's biomechanical properties. The device measures the deformation of a cutaneous area, submitted to a mechanical suction and its recovering power (Wilhelm et al., 1993). The skin viscoelastic properties are directly correlated to skin suppleness, elasticity, tonicity and firmness. The measurement will take place in the hollow of the cheek, providing a tactile measurement.

    Measured: baseline and days 56 and 84

Secondary outcomes (12)

  1. Skin hydration

    Skin hydration as measured by the Corneometer™ and the ewameter™. Measurements of the skin electrical capacitance by a Corneometer assesses the epidermal upper layers water content and quantifies the moisturizing effect of topical products. Measurement of TransEpidermal Water Loss (T.E.W.L. by aTewameter) is a non-invasive method to assess the integrity of the stratum corneum barrier function, by quantifying the water exchanges between the skin and the environment. Damage of the stratum corneum results in an increase in the T.E.W.L., leading to a more pervious skin.

    Measured: baseline and day 28

  2. Moisture retention

    Moisture retention is measured by a Tewameter™. Measurement of TransEpidermal Water Loss (T.E.W.L. by Tewameter™) is a non-invasive method to assess the integrity of the stratum corneum barrier function, by quantifying the water exchanges between the skin and the environment. Damage of the stratum corneum results in an increase in the T.E.W.L., leading to a more pervious skin. This method enables to assess and compare the protective effect of cosmetic investigational product(s) on the cutaneous barrier, after repeated applications, in the adult subject.

    Measured: baseline and day 28

  3. Skin barrier integrity

    Skin barrier integrity is measured by Tewameter™. Measurement of TransEpidermal Water Loss (T.E.W.L. by Tewameter™) is a non-invasive method to assess the integrity of the stratum corneum barrier function, by quantifying the water exchanges between the skin and the environment. Damage of the stratum corneum results in an increase in the T.E.W.L., leading to a more pervious skin. This method enables to assess and compare the protective effect of cosmetic investigational product(s) on the cutaneous barrier, after repeated applications, in the adult subject.

    Measured: baseline and day 28

  4. Pores

    A clinical evaluation of pore severity will be scored by a trained assessor. Grading will involve the use of a visual digital photographic scale designed by Qima-Newtone and the Institut d'Expertise Clinique (IEC) will assess pores on the cheek, in the area close to the nose wing. A standardized six point grading scale will be used (0-5), with a grade of 5 indicating greater severity.

    Measured: baseline and days 28, 56, and 84

  5. Texture/smoothness

    Skin texture homogeneity of the whole face will be scored by trained assessor. The participant will sit in front of the assessor under controlled conditions. A score range of 0-9, based on visual observations, will be determined. A score of 0 indicates "very heterogeneous skin (rough aspect and/or dilated pores), not uniform skin grain," whereas a score of 9 indicates "very homogeneous skin, same skin grain aspect on the concerned area."

    Measured: baseline and days 28, 56, and 84

  6. Skin tone evenness

    Clinical evaluation of visible color disorders/color imperfection will be evaluated by a trained assessor with the subject sitting in front of the assessor under controlled conditions. A score of 0 to 9 will be determined (no intermediate scores, such as fractions or decimals) will be allowed. A score of 0 indicates "no color imperfections (diffuse rednesses and/or brown shades and/or pigmented spots...)," whereas a score of 9 indicates "very marked color imperfections (diffuse rednesses and/or brown shades and/or pigmented spots...), very visible."

    Measured: baseline and days 28, 56, and 84

  7. Skin plumpness

    Clinical evaluation of skin plumpness will be evaluated by a trained assessor with the subject sitting in front of the assessor under controlled conditions. A score of 0 to 9 will be determined (no intermediate scores, such as fractions or decimals) will be allowed. A score of 0 indicates "not plump skin, lack of matter, fleshless, emaciated," whereas a score of 9 indicates "very plump skin, chubby."

    Measured: baseline and days 28, 56, and 84

  8. Radiance

    Clinical evaluation of whole face skin radiance will be evaluated by a trained assessor with the subject sitting in front of the assessor under controlled conditions. A score of 0 to 9 will be determined (no intermediate scores, such as fractions or decimals) will be allowed. A score of 0 indicates "not radiant skin, dull, does not reflect the light, not homogeneous, coarse skin grain and/or unhealthy glow," whereas a score of 9 indicates "very radiant skin, luminous, reflects the light, homogeneous, fine skin grain and/or healthy glow."

    Measured: baseline and days 28, 56, and 84

  9. Redness

    Clinical evaluation of redness visibility will be evaluated by a trained assessor with the subject sitting in front of the assessor under controlled conditions. A score of 0 to 9 will be determined (no intermediate scores, such as fractions or decimals) will be allowed. A score of 0 indicates "no redness visible," whereas a score of 9 indicates "lots of redness visible."

    Measured: baseline and days 28, 56, and 84

  10. Firmness

    Clinical evaluation of skin firmness in the hollow are of the cheek will be evaluated by a trained assessor with the subject sitting in front of the assessor under controlled conditions. A score of 0 to 9 will be determined (no intermediate scores, such as fractions or decimals) will be allowed. A score of 0 indicates "not firm skin, "flabby,"" whereas a score of 9 indicates "very firm skin, "hard.""

    Measured: baseline and days 28, 56, and 84

  11. Participant Reported Outcome: Efficacy and acceptability of product

    Self-assessment questionnaires regarding perceived efficacy and acceptability of product using a Likert response scale. The questionnaires will be provided during clinic visits and at-home assessments.

    Measured: baseline and days 14, 28, 42, 56, and 84

  12. Adverse Event Monitoring

    Adverse events will be monitored at all clinical visits. Participants will be asked immediately report any adverse reaction or any unresolved reactions or skin changes that occur during and after the study is over. Participants will document the adverse reaction, including their interpretation of the severity and time to resolution in their diaries. All suspected adverse events experienced by the participants are to be reported to the Investigator within 48 hours of occurrence, regardless of severity and resolution. The Investigator or designee will evaluate all product-related AEs as to their severity and causality, using standardized definitions.

    Measured: Up to two weeks after study completion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Aug 2026
  2. Study start17 Aug 2026
  3. Primary completion4 Dec 2026 (estimated)
  4. Study completion31 Mar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
140 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07774000
Sponsor's protocol ID
C26-Z083
Acronym
NR-RADIANCE
Status last verified
Aug 2026
First submitted
16 Aug 2026
Last updated
21 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Data may be made available upon reasonable request following the publication of the primary study results.

Publications

  • Wilhelm KP, Cua AB, Maibach HI. In vivo study on age-related elastic properties of human skin. In Noninvasive Methods for the Quantification of Skin Functions: An Update on Methodology and Clinical Applications 1993 (pp. 190-203). Berlin, Heidelberg: Springer Berlin Heidelberg.

  • Pinnagoda J, Tupker RA, Agner T, Serup J. Guidelines for transepidermal water loss (TEWL) measurement. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis. 1990 Mar;22(3):164-78. doi: 10.1111/j.1600-0536.1990.tb01553.x.

    PubMed 2335090

  • Loden M. Biophysical properties of dry atopic and normal skin with special reference to effects of skin care products. Acta Derm Venereol Suppl (Stockh). 1995;192:1-48. doi: 10.2340/00015555192148.

    PubMed 7653198

  • Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. doi: 10.1371/journal.pone.0042357. Epub 2012 Jul 27.

    PubMed 22848760

  • Idoine, R.; Amini-Nik, S.; Mavoyan, J.; Nkrumah-Elie, Y.; Diaz, J.; Shioya, E. Irritation Potential and Acute Efficacy of Topically Applied Niagen® (Niacinamide Riboside Chloride). Preprints 2026, 2026031657. https://doi.org/10.20944/preprints202603.1657.v1

Questions about this trial

What is this clinical trial studying?

A study testing Topical niacinamide riboside in people with Skin Aging on Face and Skin Care Dermocosmetics, run by ChromaDex, Inc. at 1 site in South Africa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Manoj Choudhry (+27 21 204 4886, manoj.choudhry@iecas.co.za), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in skin's biological age (time frame: baseline and day 84). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07774000, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in